The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

BACKGROUND: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can select L76V. Beside an enhancement of resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiesmann, Frank, Vachta, Jan, Ehret, Robert, Walter, Hauke, Kaiser, Rolf, Stürmer, Martin, Tappe, André, Däumer, Martin, Berg, Thomas, Naeth, Gudrun, Braun, Patrick, Knechten, Heribert
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049128/
https://www.ncbi.nlm.nih.gov/pubmed/21314993
http://dx.doi.org/10.1186/1742-6405-8-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049128/
https://www.ncbi.nlm.nih.gov/pubmed/21314993
http://dx.doi.org/10.1186/1742-6405-8-7

Ejemplares similares